| Hu, Chaur-Jong |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
| Chen, Wei |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT05721404: Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis |
|
|
| Recruiting | 4 | 194 | RoW | Icodextrin Peritoneal Dialysis Solution, Hypertonic Dextrose solution | First Affiliated Hospital, Sun Yat-Sen University, Baxter Healthcare Corporation | Peritoneal Dialysis | 04/25 | 12/25 | | |
NCT06720233: Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis |
|
|
| Completed | 3 | 37 | RoW | SAL-0951 tablets, SAL-0951 group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 10/24 | 10/24 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT06720025: Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis |
|
|
| Completed | 3 | 100 | RoW | SAL-0951 tablets, SAL-0951 group, rHuEPO injection, rHuEPO group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 06/24 | 06/24 | | |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 05/25 | 05/26 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2/3 | 230 | Canada, US | MN-166, ibudilast, placebo | MediciNova | Amyotrophic Lateral Sclerosis | 12/25 | 12/26 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06435182: Study of OT202 in Treating Moderate to Severe Dry Eye |
|
|
| Completed | 2 | 213 | RoW | OT202 conc 0.5%, Investigational product, OT202 conc 0.1%, Placebo | Ocumension Therapeutics (Shanghai) Co., Ltd | Dry Eye | 01/24 | 01/24 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 07/25 | 09/25 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT06474416: A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis |
|
|
| Recruiting | 1 | 16 | RoW | BD111 Injection (Investigative New Drug), BD111 Lentivirus-like particles, HSV-1-erasing lentiviral particles, HELP, Triple-drugs therapy of HSV-1 stromal keratitis, Ganciclovir Ophthalmic Gel, Valacyclovir Hydrochloride Tablets, Prednisolone Acetate Ophthalmic Suspension | Shanghai BDgene Co., Ltd. | Herpes Simplex Virus Type I Stromal Keratitis | 09/25 | 09/25 | | |
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS |
|
|
| Recruiting | 1 | 64 | Europe, Canada | Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo | QurAlis Corporation | Amyotrophic Lateral Sclerosis | 08/26 | 08/26 | | |
NCT05570435: Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response |
|
|
| Completed | N/A | 31 | RoW | Blood collection | Société des Produits Nestlé (SPN), Peking Union Medical College Hospital | Healthy, PreDiabetes, Adult, Asian | 03/23 | 03/23 | | |
NCT05859165: To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes) |
|
|
| Recruiting | N/A | 250 | RoW | Nutren Diabetes, Fresubin Diabetes | Société des Produits Nestlé (SPN), Nestle Health Science | Diabetes Mellitus | 12/24 | 06/25 | | |
| Choi, Seong Ho |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Active, not recruiting | 3 | 1083 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 05/25 | 05/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2 | 282 | Europe, Canada, US, RoW | GSK4527226, Placebo | GlaxoSmithKline, Alector Inc. | Alzheimer's Disease | 12/26 | 02/29 | | |
| Gu, Ping |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT03550183: Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease |
|
|
| Enrolling by invitation | 1 | 20 | RoW | mesenchymal stem cells | Hebei Newtherapy BIo-Pharma technology Co., Ltd. | Parkinson's Disease | 10/22 | 12/22 | | |
| Macfarlane, Stephen |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Completed | 2/3 | 300 | Europe, Canada, RoW | ANAVEX2-73, Blarcamesine | Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH | Alzheimer Disease | 06/24 | 06/24 | | |
| Wu, Mai-Szu |
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD |
|
|
| Completed | 3 | 141 | RoW | Ferric citrate, Placebo | Panion & BF Biotech Inc. | Anemia of Chronic Kidney Disease | 10/22 | 12/22 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 3 | 685 | Europe, Canada, US, RoW | Renal Autologous Cell Therapy (REACT), Sham Comparator | Prokidney, Iqvia Pty Ltd, PPD | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 02/27 | 02/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT02933827: Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease |
|
|
| Completed | 1/2 | 39 | RoW | ELIXCYTE | UnicoCell Biomed CO. LTD, Protech Pharmaservices Corporation (PPC) | Moderate to Severe Chronic Kidney Disease | 04/19 | 06/23 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Lee, Kang-Yun |
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Active, not recruiting | 3 | 641 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 950 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo | Regeneron Pharmaceuticals | Non-small Cell Lung Cancer | 01/30 | 12/31 | | |
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 850 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer | 03/30 | 02/32 | | |
|
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) |
|
|
| Recruiting | 1 | 30 | US, RoW | Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab | Acepodia Biotech, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 12/26 | 03/27 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
NCT04909034: A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer |
|
|
| Completed | N/A | 15 | RoW | MS-20, Chemo young, Placebo | Microbio Co Ltd | NSCLC Stage IIIB~IV | 10/24 | 11/24 | | |
| Rewerska, Barbara |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (). |
|
|
| Active, not recruiting | 3 | 837 | Europe, RoW | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 07/25 | 09/25 | | |
| Suspended | 3 | 675 | Europe, Canada, US, RoW | Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo | Anji Pharma | Diabetes Mellitus, Type 2 | 12/23 | 06/24 | | |
SCALP2, NCT05914805: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | Europe, US | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 08/24 | 03/25 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD |
|
|
| Active, not recruiting | 3 | 3433 | Europe, Canada, US, RoW | Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | COPD, COPD Exacerbation | 01/26 | 01/26 | | |
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy |
|
|
| Recruiting | 2 | 450 | Europe, Canada, Japan, US, RoW | LY3848575, Placebo | Eli Lilly and Company | Neuropathic Pain, Distal Sensory Polyneuropathy | 06/26 | 09/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
| Lee, Woan-Ruoh |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
NCT05719649: The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial |
|
|
| Not yet recruiting | N/A | 72 | NA | Lactic acid bacteria NTU 101, Placebo | SunWay Biotech Co., LTD. | Atopic Dermatitis, Atopic Dermatitis Eczema | 05/23 | 05/23 | | |
| Kawashima, Kayoko |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
| Boutoleau-Bretonierre, Claire |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Kolinek, Joanna |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
| Borzova, Claudia Vodickova |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
